Skip to main content
Clinical Trials/NCT02665871
NCT02665871
Unknown
Phase 1

Safety Study of Freeze-dried Live Attenuated Influenza Vaccine for Intranasal Administration in Chinese Adults Aged 3 Years and Older

Beijing Chaoyang District Centre for Disease Control and Prevention0 sites80 target enrollmentMarch 2016
ConditionsInfluenza

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Influenza
Sponsor
Beijing Chaoyang District Centre for Disease Control and Prevention
Enrollment
80
Primary Endpoint
Evaluate the rate of adverse reactions of Live Attenuated Influenza Vaccine for Intranasal Administration
Last Updated
9 years ago

Overview

Brief Summary

This study evaluates the safety of freeze-dried live attenuated influenza vaccine for intranasal administration in chinese adults aged 3 years and older.80 subjects will be divided into 2 groups, including 18 years and older and 3-17 years old. Subjects in each groups will randomly receive one dose of influenza vaccine or placebo in a 3:1 ratio.

Registry
clinicaltrials.gov
Start Date
March 2016
End Date
September 2016
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Beijing Chaoyang District Centre for Disease Control and Prevention
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Healthy subjects more than 3 years
  • Guardian and/or subjects aged at least 10 subjects can be informed consent, and sign a written Informed Consent Form.
  • Subjects, Guardians and his family can obey the demands of the scheme .
  • Axillary temperature less than 37℃

Exclusion Criteria

  • Subjects with flu or infected with flu within 3 months.
  • Subjects have a vaccine allergies, allergic to any kind of composition in experimental vaccine, such as eggs, ovalbumin etc.
  • Subjects have serious side effects to vaccine, such as allergy, urticaria, skin eczema, dyspnea, angioneurotic edema or abdominal pain.
  • Subjects have symptoms of acute infection within a week.
  • Subjects have autoimmune disease or immune function defect, Subjects have used immunosuppressive therapy, cytotoxic treatment or inhaled corticosteroids in the past 6 months.
  • Subjects have congenital malformations, developmental disorder or serious chronic diseases( such as Down's syndrome, diabetes, Sickle cell anemia or nerve system disease)
  • Subjects have asthma unstable that need emergency treatment, hospitalization, intubation, oral or intravenous corticosteroid in the past 2 years.
  • Subjects have medical history or family history of convulsions, seizures, encephalopathy and psychiatric disease.
  • Alienia, functional asplenia, and alienia or splenectomy in any situation.
  • Serious neurological disorders such as Green Barry syndrome.

Outcomes

Primary Outcomes

Evaluate the rate of adverse reactions of Live Attenuated Influenza Vaccine for Intranasal Administration

Time Frame: 3 months

Adverse reactions associated with vaccine will be observed in subjects after vaccination. Solicited local adverse events include Pain, Redness, Swelling, Induration, Rash, Pruritus at injection site. solicited general adverse events include Fever, Nausea, Vomiting, Diarrhea, Decreased appetite, Be agitated (irritability, abnormal crying), fatigue, allergy

Similar Trials